Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Siva, A.
Right arrow Articles by Senocak, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siva, A.
Right arrow Articles by Senocak, M.
Related Collections
Right arrow Migraine
NEUROLOGY 2008;70:1337-1345
© 2008 American Academy of Neurology

Validity of the ID-Migraine screener in the workplace

A. Siva, MD, M. Zarifoglu, MD, M. Ertas, MD, S. Saip, MD, H. N. Karli, MD, B. Baykan, MD, A. Keskinaslan, MD and M. Senocak, PhD

From the Departments of Neurology (A.S., S.S.) and Biostatistics (M.S.), Cerrahpasa Medical School of Istanbul University; Department of Neurology (M.Z., H.N.K.), Medical School of Uludag University, Bursa; Department of Neurology (M.E., B.B.), Istanbul Medical School of Istanbul University; and Department of Neurology Outcomes Research (A.K.), Pfizer, Istanbul, Turkey.

Address correspondence and reprint requests to Dr. Aksel Siva, Istanbul University Cerrahpasa School of Medicine, Department of Neurology, Istanbul, Turkey asiva{at}tnn.net

Objective: The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce.

Methods: A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria.

Results: A total of 227 subjects (mean age 31.9 ± 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 ± 9.5 days for migraine-positive and 4.9 ± 6.6 days for migraine-negative subjects.

Conclusion: The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.

Abbreviations: HIT = Headache Impact Test; ICHD-2 = International Classification of Headache Disorders, 2nd edition; ID-Ms = ID-Migraine screener; MIDAS = Migraine Disability Assessment Questionnaire; NPV = negative predictive value; PPV = positive predictive value; SF-36 = 36-Item Short Form Health Survey.

Supported by an unrestricted educational grant from Pfizer Ilaclari Ltd. Sti., Turkey.

Disclosure: The authors report no conflicts of interest.

Received November 2, 2006. Accepted in final form September 21, 2007.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.